Meeting
2015 ASCO Annual Meeting
MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
Authors
Paul G. Richardson
Dana-Farber Cancer Institute, Boston, MA
Paul G. Richardson , Amine Bensmaine , Thomas Doerr , Jianming Wang , Mohamed H. Zaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01734928
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS8610)
DOI
10.1200/jco.2015.33.15_suppl.tps8610
Abstract #
TPS8610
Poster Bd #
423b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
First Author: Pieter Sonneveld
Poster
2013 ASCO Annual Meeting
Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.
First Author: David Samuel DiCapua Siegel
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.
First Author: Xavier Leleu
Poster
2018 ASCO Annual Meeting
Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.
First Author: Robert Z. Orlowski